Vonicog alfa (rVWF) use in children with von Willebrand disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational follow-up of pediatric patients in Japan who are given vonicog alfa (rVWF) as part of routine care for bleeding episodes or around surgery. Investigators will record adverse drug reactions and clinical effectiveness for one year after the start of rVWF administration. Treatment decisions are made by the patients' physicians under normal practice and the sponsor will only collect data on what happens. Patients already enrolled in other rVWF clinical trials are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria :

* Under 18 years old with vWD.
* Participants who are treated with rVWF for the purpose of hemostatic treatment and management during bleeding episodes or perioperative periods.
* Participants who have prescription or administration after the approval date of rVWF for pediatric use in Japan.

Exclusion Criteria :

\- Patients who are participating in clinical trials of rVWF.

Where it's running

• Takeda selected site
  Tokyo, Tokyo, Japan Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SR604 in Von Willebrand Disease: a Phase II study to see if it helps with bleeding

  This Phase 2 trial tests SR604 in adults with von Willebrand disease to see if it can improve bleeding control and how the drug behaves in the body.

  Recruiting at 9 sites Phase 2 Shanghai RAAS Blood Products Co., Ltd. · Changsha and 8 other locations · NCT07640893

• ALN-6400 for women with von Willebrand disease and heavy menstrual bleeding

  This study tests ALN-6400 to see if it can help reduce heavy menstrual bleeding in adult and adolescent women with von Willebrand disease.

  Recruiting Phase 2 Alnylam Pharmaceuticals · Orange, California and 20 other locations · NCT07575308

• Endothelial colony-forming cell behavior in people with von Willebrand disease and acquired von Willebrand syndrome

  This project will see how endothelial colony-forming cells (ECFCs) behave in people with VWD or AVWS compared with healthy volunteers.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07358013

• VONVENDI treatment for adults in China with von Willebrand disease

  We will test whether VONVENDI is safe and helps control bleeding in adult Chinese patients with severe von Willebrand disease, sometimes given with ADVATE if their factor VIII is low.

  Recruiting at 7 sites Phase 3 Takeda · Beijing and 6 other locations · NCT07129343

• Subcutaneous VGA039 to prevent bleeds in people with von Willebrand disease

  This study will test whether subcutaneous VGA039 can reduce bleeding in people aged 12–75 with any type of von Willebrand disease who have frequent bleeds.

  Recruiting at 32 sites Phase 3 Vega Therapeutics, Inc · Little Rock, Arkansas and 31 other locations · NCT07115004

• Assessing HMB-002 for treating Von Willebrand Disease

  This study is testing a new treatment called HMB-002 to see if it is safe and effective for adults with Type 1 Von Willebrand Disease.

  Recruiting at 6 sites Phase 1/2 Hemab ApS · Phoenix, Arizona and 24 other locations · NCT06754852

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.